Patent ID: 7638125
Filing Date: 2009-12-29
Classification: A61K,A61P,C07K,Y10S

Abstract:
1. A pharmaceutical composition comprising a first antibody or a binding fragment thereof and a second antibody or a binding fragment thereof, having the capability to bind to different epitopes located on an ErbB1 receptor molecule, wherein said first antibody molecule or a portion thereof comprises a binding site that bind to a first specific epitope on the ErbB1 receptor molecule, and said second antibody molecule comprises a binding site that binds to a second specific different epitope on said ErbB1 receptor molecule, wherein said first and said second epitopes on the ErbB1 receptor molecule are located within the ErbB1 receptor ligand-binding domain, thereby increasing the amount of antibody bound per receptor and per cell by the same antibody dose and causing an enhanced ErbB1 blocking or inhibition and induction of down-regulation of ErbB1 receptor-specific pathway signaling as compared with a composition comprising said first or second antibody molecule only, wherein said first antibody is humanized MAb 425 (h425) and said second antibody is chimeric MAb 225 (c225).